Marianne R Spalinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9335022/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. Nature Communications, 2017, 8, 98.	12.8	224
2	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut, 2017, 66, 1216-1224.	12.1	223
3	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Journal of Clinical Investigation, 2016, 126, 1783-1800.	8.2	171
4	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. Autophagy, 2017, 13, 1590-1601.	9.1	90
5	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. Cell Reports, 2018, 22, 1835-1848.	6.4	80
6	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS ONE, 2016, 11, e0154817.	2.5	71
7	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host and Microbe, 2021, 29, 1573-1588.e7.	11.0	71
8	PTPN2 Regulates Interactions Between Macrophages and Intestinal Epithelial Cells to Promote Intestinal Barrier Function. Gastroenterology, 2020, 159, 1763-1777.e14.	1.3	62
9	Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-γ–Induced Signaling in Human Monocytes. Gastroenterology, 2013, 144, 978-988.e10.	1.3	46
10	β ₆ â€integrin serves as a novel serum tumor marker for colorectal carcinoma. International Journal of Cancer, 2019, 145, 678-685.	5.1	42
11	The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. Mucosal Immunology, 2019, 12, 733-745.	6.0	40
12	Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy. PLoS ONE, 2013, 8, e72384.	2.5	38
13	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. Journal of Lipid Research, 2019, 60, 1270-1283.	4.2	37
14	Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. Journal of Crohn's and Colitis, 2017, 11, 871-884.	1.3	35
15	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS ONE, 2018, 13, e0199664.	2.5	35
16	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. Journal of Experimental Medicine, 2021, 218, .	8.5	33
17	Role of Protein Tyrosine Phosphatases in Regulating the Immune System. Inflammatory Bowel Diseases, 2015, 21, 645-655.	1.9	32
18	The JAK Inhibitor Tofacitinib Rescues Intestinal Barrier Defects Caused by Disrupted Epithelial-macrophage Interactions. Journal of Crohn's and Colitis, 2021, 15, 471-484.	1.3	30

#	Article	IF	CITATIONS
19	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. World Journal of Gastroenterology, 2016, 22, 1034.	3.3	28
20	Crohn's Disease: Loss of Tolerance or a Disorder of Autophagy?. Digestive Diseases, 2014, 32, 370-377.	1.9	23
21	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. Mucosal Immunology, 2019, 12, 1336-1347.	6.0	21
22	Ingested nano- and microsized polystyrene particles surpass the intestinal barrier and accumulate in the body. NanoImpact, 2022, 25, 100374.	4.5	20
23	Stepwise Development of an in vitro Continuous Fermentation Model for the Murine Caecal Microbiota. Frontiers in Microbiology, 2019, 10, 1166.	3.5	19
24	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. Journal of Crohn's and Colitis, 2019, 13, 785-797.	1.3	19
25	T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling. Journal of Clinical Investigation, 2021, 131, .	8.2	18
26	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	8.2	16
27	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. Journal of Clinical Investigation, 2019, 129, 2527-2541.	8.2	15
28	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. Frontiers in Immunology, 2020, 11, 1856.	4.8	14
29	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. Journal of Crohn's and Colitis, 2019, 13, 798-806.	1.3	13
30	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. Inflammatory Intestinal Diseases, 2021, 6, 140-153.	1.9	13
31	The autoimmune susceptibility gene, <i>PTPN2</i> , restricts expansion of a novel mouse adherent-invasive <i>E. coli</i> . Gut Microbes, 2020, 11, 1547-1566.	9.8	12
32	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. Digestion, 2016, 93, 249-259.	2.3	11
33	The Role of Protein Tyrosine Phosphatases in Inflammasome Activation. International Journal of Molecular Sciences, 2020, 21, 5481.	4.1	11
34	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF- <i>α</i> Overexpression in Crohn Disease–Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. Inflammatory Bowel Diseases, 2021, 27, 538-549.	1.9	11
35	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion, 2016, 93, 182-192.	2.3	10
36	Loss of protein tyrosine phosphatase non-receptor type 2 reduces IL-4-driven alternative macrophage activation. Mucosal Immunology, 2022, 15, 74-83.	6.0	10

#	Article	IF	CITATIONS
37	Autoimmune susceptibility gene <i>PTPN2</i> is required for clearance of adherent-invasive <i>Escherichia coli</i> by integrating bacterial uptake and lysosomal defence. Gut, 2022, 71, 89-99.	12.1	9
38	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PLoS ONE, 2016, 11, e0160215.	2.5	7
39	The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis. United European Gastroenterology Journal, 2016, 4, 325-332.	3.8	7
40	PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation. Molecular and Cellular Oncology, 2018, 5, e1465013.	0.7	7
41	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. PLoS ONE, 2018, 13, e0193003.	2.5	7
42	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. Inflammatory Intestinal Diseases, 2019, 4, 161-174.	1.9	6
43	Protection against autoimmunity is driven by thymic epithelial cell–mediated regulation of T _{reg} development. Science Immunology, 2021, 6, eabf3111.	11.9	6
44	Gastroresistant oral peptide for fluorescence imaging of colonic inflammation. Journal of Controlled Release, 2017, 262, 118-126.	9.9	5
45	Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine. Inflammatory Bowel Diseases, 2020, 26, 1038-1049.	1.9	5
46	Loss of PTPN22 Promotes Intestinal Inflammation by Compromising Granulocyte-mediated Antibacterial Defence. Journal of Crohn's and Colitis, 2021, 15, 2118-2130.	1.3	5
47	Energy Drink Administration Ameliorates Intestinal Epithelial Barrier Defects and Reduces Acute DSS Colitis. Inflammatory Bowel Diseases, 2021, 27, 1139-1152.	1.9	4
48	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflammatory Bowel Diseases, 2021, 27, 1986-1998.	1.9	4
49	Mono Sodium Urate Crystal-induced Peritonitis for in vivo Assessment of Inflammasome Activation. Bio-protocol, 2018, 8, e2754.	0.4	4
50	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis. International Journal of Molecular Sciences, 2021, 22, 6820.	4.1	3
51	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. Inflammatory Intestinal Diseases, 2017, 2, 211-218.	1.9	1
52	Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23. Inflammatory Intestinal Diseases, 2019, 4, 14-26.	1.9	1
53	Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. Digestion, 2021, 102, 453-461.	2.3	1
54	Loss of PTPN2 Activity Alters Iron Handling Protein Expression in IBD Patients and Causes Iron Deficiency in Mice. FASEB Journal, 2022, 36, .	0.5	0